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Introduction: Mavoglurant is a noncompetitive antagonist at the 
metabotropic glutamate receptor 5 (mGluR5) currently being inves-
tigated as oral treatment of Parkinson’s disease–associated levodopa-
induced dyskinesia (PD-LID) and fragile X syndrome (FXS). This 
study evaluated the impact of single therapeutic and supratherapeutic 
intravenous (IV) doses of mavoglurant on the QTc interval duration 
in healthy subjects in compliance with the ICH E14 guideline.
Patients (or Materials) and Methods: In a pilot-phase, the safety 
and tolerability of single, ascending IV doses of 25 mg, 37.5 mg, 
and 50 mg of mavoglurant was assessed in 36 healthy subjects (n = 
12 per dose level). Subsequently, a randomized, placebo- and active-
controlled, 4-period, single-center, crossover thorough QTc study has 
been conducted in 76 healthy subjects with the following single-dose 
treatments: therapeutic and supratherapeutic dose of mavoglurant, 
400-mg moxifloxacin, and placebo. Mavoglurant was administered 
intravenously in a double-blind fashion, while the positive control 
moxifloxacin was orally administered in an open-label fashion. 
Holter ECG monitoring was performed up to 24 hours postdosing, 
and QTc data were derived from triplicate ECGs extracted at 3 pre-
dose (= baseline) and 12 postdose time points.
Results: An acceptable safety and tolerability of mavoglurant was 
confirmed at single IV doses of 25 mg, 37.5 mg, and 50 mg according 
to predefined criteria. Hence, doses of 25-mg and 50-mg mavoglurant 
were selected as therapeutic and supra-therapeutic dose for the core 
TQT study. The upper bound of the 90% 2-sided CI of the placebo 
and baseline-corrected QTcF (= Δ Δ QTcF) did not exceed 10 ms at 
any postdose time point for both doses of 25-mg and 50-mg mavo-
glurant. The maximum QTcF prolongation of 1.98 ms (90% CI, 
0.58–3.38) on 25 mg and 1.49 ms (90% CI, 0.10–2.88) on 50 mg 
were observed 3 hours’ postdosing. The PK/PD analysis confirmed 
the lack of an association between AFQ056 plasma concentrations 
and Δ Δ QTcF data over the entire range of Cmax data at 25-mg and 
50-mg mavoglurant (r2 < 0.01). An outlier analysis showed no sub-
jects with newly identified QTcF intervals > 480 ms or any QTcF pro-
longation > 60 ms compared with baseline in any treatment group. 
Study validity was confirmed given that the lower bound of the 90% 
CI of Δ Δ QTcF for moxifloxacin was > 5 ms at 4 predefined postdose 
time points (1, 2, 3, and 4 hours) (Bonferroni-adjusted P < 0.0125).
Conclusion: In this thorough QTc study, the lack of any clinically 
relevant QTc prolongation was demonstrated for both therapeutic 
and supratherapeutic single IV doses of 25-mg and 50-mg mavo-
glurant.
Disclosure of Interest: M. Ufer: Shareholder of Novartis Pharma, 
employee of Novartis Pharma.
PP245—IN-VITro bIoaSSay of 1,5 - dImeThyl 
CITraTe moNohydraTe; a ComPouNd 
ISolaTed from The fruIT of maNgIfera 
INdICa (aNaCardIaCeae)
F. Khan1*; E. Olowononi1; M. Garba1; and A. lawal2
1Department of Pharmacology and Therapeutics, Ahmadu 
Bello University, Zaria, Nigeria; and 2School of Pharmaceutical 
Sciences, Universiti Sains Malaysia, Penang, Malaysia
Introduction: In this study, an in vitro bioassay of 1,5-dimethyl 
citrate monohydrate was carried out; 1,5-dimethyl citrate mono-
hydrate is a hydrated citric acid derivative with molecular formula 
C8H12O7·H2O isolated from Mangifera indica fruit
Patients (or Materials) and Methods: To support the hypothesis that 
the compound may have effect on smooth muscles, the activity of this 
pure compound on the longitudinal smooth muscles of isolated guinea 
pig ileum, rabbit jejunum, and guinea pig trachea was determined.
Results: Graded doses of the compound (0.5 mg/mL and 1 mg/
mL) showed a dose-dependent increase in contraction of the lon-
gitudinal smooth muscle of the isolated guinea pig ileum similar to 
histamine, and this contraction was antagonized by mepyramine. 
The compound was thus speculated to be a histaminergic agonist, 
which acts on the H1 histamine receptors found on smooth muscles. 
Activation of these H1 receptors in smooth muscle cells causes an 
increase in phosphoinositol hydrolysis and increase in intracellular 
calcium which brings about contraction of intestinal smooth muscle. 
The compound, however, at a concentration of 1 mg/mL produced 
no remarkable effect on the rabbit jejunum. Because the compound 
did not produce any remarkable effect on the rabbit jejunum, it is 
possible to speculate that the compound 1,5-dimethyl citrate mono-
hydrate at 1 mg/mL does not activate the cell specific receptors on 
the smooth muscles neither does it interact with voltage-operated 
Ca2+ channel. The compound also at a concentration of 5 mg/mL 
produced no appreciable response on guinea pig trachea.
Conclusion: This suggests that the compound may not interact with 
the receptors present to cause any remarkable response.
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Introduction: Melitor®/agomelatine/ is an melatonergic antidepres-
sant developed by the pharmaceutical company Servier. It is marketed 
for the treatment of major depressive disorder and has been reported 
to have a reduced level of sexual side effects as well as discontinuation 
effects compared with some other antidepressants. Agomelatine may 
also have positive effects on sleep.
Patients (or Materials) and Methods: According to Serbian Law 
on Medicinal Products and Medical Devices, regulatory procedural 
steps taken for getting Marketing Authorisation Approval in Serbia, 
started on 2011 year. Assesment of submitted documentation/Module 
1-5 Common Technical Document/ lasted longer, because of waiting 
additional regulatory data requested from the manufacturer.
Results: After evaluation submitted documentation by ALIMS’s 
Assessors, and re-evaluation the same documentation by the 
experts that are in Advising Working Group for medicinal products 
of Medicines and Medical Devices Agency of Serbia , the ALIMS 
requested again additional data related to efficacy and safety of this 
drug. The explanation of this action was: Mechanism of action of 
agomelatin does not support the pharmacotherapeutic principles of 
threating major depression.
Results of submitted clinical trials did not prove the efficacy of 
this drug. After oral administration, pharmacokinetic results showed 
nonlinearity in wide dose range and rough proportionality inside 
the therapeutic dose range. As postmarketing follow-up reports, 
applicant for getting Marketing Authorization Approval submitted 
4 Periodic Update Repotrs / PSURs/. On the basis of these PSURs, it 
could not be concluded that benefit/ risk assessment of agomelatin 
in the treatment of major depression is positive.
Conclusion: After several meetings, relevant ALIMS’ experts sug-
gested refusal of Melitor® registration. The regulatory story is still 
lasting, because applicant lodged the complaint on ALIMS’ decision 
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to Republic Ministry of health of Serbia. In next regulatory step, after 
getting demand of Ministry of health of Serbia, ALIMS experts have 
to re-evaluate all registration documentation and their own decision 
in order to issue final decision.
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Introduction: BRINAVESS® /vernakalant/ is an antiarrhythmic med-
icine that acts preferentially in the atria to prolong atrial refractori-
ness and to rate dependently slow impulse. Anatomical Therapeutic 
Chemical Classification/ATC/ is: C01BG11.
Patients (or Materials) and Methods: According to Serbian Law 
on Medicinal Products and Medical Devices, regulatory procedural 
steps taken for getting Marketing Authorisation Approval in Serbia, 
started on 2011 year.
Results: After evaluation and reevaluation of submitted documenta-
tion/Module 1-5 Common Technical Document/, Advising Working 
Group for medicinal products of Medicines and Medical Devices 
Agency of Serbia suggested refusal application. On June 2012.year 
ALIMS issued the final decision/No. 515-01-0020-11-003/ about 
refusal registration. The reasons are related to divergence of facts 
cited in Summary Product Characteristics and pre-registration clini-
cal trials’ results devoted to efficacy, safety, statistical significance 
of total number of patients included in clinical phase of drug devel-
opment, as well as suspicion about the drug quality. Although the 
applicant declared that specified impurity limits in active substance 
are in accordance with preclinical toxicological testing, these results 
did not existed in Drug Master File, so the ALIMS assessor concluded 
that this applicant’s statement is not true.
Conclusion: Impossibility to submit requested additional revelant 
regulatory data caused applicant’s claim on March 2013.year for 
withdrawing registration of BRINAVESS® in Serbia.
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Introduction: Study of ethical aspects of relationships of pharma-
cists and patients during rendering of pharmaceutical services for 
the purpose of improving effectivness and safety of pharmacotherapy 
of patients.
Patients (or Materials) and Methods: A social poll using a method 
of selective anonymous survey of pharmacists and customers. The 
objects of research were the chemist’s shops of the city of Bishkek 
determined randomly. The analysis is based on the survey of 121 
pharmacists and 207 patients. The pharmacists were 45 (37.2%) 
specialists with university education and 76 (62.8%) with college 
education, the average age was 31.4 and the work of experience in 
pharmacy was 7.2 years. The patients were respondents older 18 
years old. The age distribution was 28.8% for 18–27; 34.6% for 
28–37; 9.7% for 38–47; 22.7% for 48 –57 and 4.2% for older 60. 
In terms of gender, the customers broke down into 133 (64.3%) 
female and 76 (35.7%) male. 45.3% of them had a university edu-
cation, 32.7% had a college education, and 21,9% were students. 
The received data were processed with the help of specialized SPSS 
statistical software package.
Results: According to the processed data most pharmacists (72,7%) 
know about the Code of Ethics for pharmacy practice and its con-
tents. All specialists (100%) admit that customers have the right to 
receive the information about the medicine they buy. As pharmacists 
note (64.5%), customers are most often interested in dosage and 
proper use of medicines. 63.6% of patients need professional assis-
tance when they choose a medicine. However, 27.1% of patients 
say pharmacists give consultations reluctantly. In the course of the 
research, customers of the chemist’s shops were suggested to evaluate 
some indices reflecting the degree of their satisfaction by pharmacists’ 
work (10-point scale). The average evaluation of the indices, such 
as appearance, consideration, tactfulness, patience and the ability 
to turn medical notions into plain language was 7.5. According to 
23.4% of pharmacists the most often reason of conflicts in chemist’s 
shops is patients’ dissatisfaction with a price of a medicine. This is 
confirmed by 67.7% patients thinking that most pharmacists are 
oriented for selling expensive and advertised medicines regardless 
of other affordable generics which do not concede in quality and 
effectiveness.
Conclusion: The research has revealed significant gaps in profes-
sional ethics of pharmacists. This allows us to make a conclusion that 
measures of interference in relationships of pharmacists and patients 
in the process of rendering pharmaceutical services need to be taken.
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Introduction: CXCL10 is a potent mast cell chemoattractant respon-
sible for the mast cell myositis characteristic of asthma. We have 
identified human airway smooth muscle (HASM) as a rich source 
of CXCL10 which is increased by TNF-alpha and IFN-gamma. We 
have previously shown that beta-agonists inhibit TNF-alpha induced 
CXCL10 release but the effect is lost when IFN-gamma is given 
concomitantly through poorly defined mechanisms. Here we defined 
the mechanism involved.
Patients (or Materials) and Methods: HASM cells taken from 3 nor-
mal donors were cultured using standard techniques. ELISA was 
used for quantitative measurement of CXCL10 release. Cyclic AMP 
assay was used to measure the cAMP level. Western Blot was used 
to indicate CREB phosphorylation.
Results: We found that salmeterol time dependently increased cAMP 
generation. TNF-alpha or IFN-gamma alone or in combination had 
similar effects on salmeterol time dependently induced cAMP genera-
tion suggesting that the inhibitory effect of IFN-gamma on beta-2 
agonist signaling was not at the level of cAMP generation but rather 
was likely to be an effect on downstream signaling pathways. Next 
we looked at the phosphorylation of CREB by Western blot and 
found that salmeterol and caused phosphorylation of CREB but this 
was differentially affected by the cytokines. Whereas TNF-alpha 
